

PERSONAL INFORMATION **Hans Van Vlierberghe**

WORK EXPERIENCE

May 1995- Present **Head of Department/Professor**
Ghent University Hospital (Belgium)
Gastroenterology and Hepatology, Liver Transplantation.

EDUCATION AND TRAINING

July 1989- Present **PhD**
GHent University Hospital (Belgium)
Internal medicine, Gastroenterology, Hepatology

ADDITIONAL INFORMATION

Expertise Hepatology
Viral hepatitis
Primary Liver cancer
Liver Transplantation

Publications 1.1 Bijlage 1
PUBLICATIONS
BOEKEN.

(b2)

Van Vlierberghe, Hans; Elewaut, A. Surgical risk in patients with liver disease. Chapter in Problem solving in hepatobiliary diseases: vol. 4 (1999). ISBN 9074512593

Vanderschaeghe D, Debruyne E, Van Vlierberghe H, Callewaert N, Delanghe J. CE analysis of gamma-globulin mobility and potential clinical utility. In: Methods in Molecular Biology: Clinical Applications of Capillary Electrophoresis. © Humana Press, a part of Springer Science + Business Media (publication planned in 2012).

ARTIKELS.

(a1)

1. H. Van Vlierberghe, M. De Vos, G. De Cock, C. Cuvelier, A. Elewaut. Fundic gland polyps ; three other case reports suggesting a possible association with acid suppressing therapy. Acta Gastroenterol Belg 1997 ; 60 : 240-242. (Impact factor: 0.83)
2. D. Elewaut, N. Van Damme, F. de Keyser, D. Baeten, P. De Paepe, H. Van Vlierberghe, H. Mielants, C. Cuvelier, G. Verbruggen, E.M. Veys, M. De Vos. Altered expression of alphaEbeta7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease. Acta Gastroenterologica Belgica 1998 ; 61 : 288-294. (Impact factor: 0.83)
3. H. Van Vlierberghe, P. Duyck, P. Bernard, C. Braxel, J. Versieck (), A. Elewaut. Multifocal fatty infiltration of the liver ; an aspecific presentation form of hepatitis C infection. Acta Gastro-enterologica Belgica 1998 ; 61 : 379-381. (Impact factor: 0.83)
4. H. Van Vlierberghe, K.J. Mortelé. Mediastinal mass in a patient with cirrhosis. Journal of Hepatology 1998; 29 : 1004. (Impact factor: 7.1)
5. M.L. Hautekeete, I. Colle, H. Van Vlierberghe, A. Elewaut. Symptomatic liver injury probably related to sertraline. Gastroenterologie Clinique Biologique 1998 ; 22 : 364-365. (Impact factor: 1.0)
6. Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. Journal of Hepatology 1998 ; 28 : 960-964. (Impact factor: 7.1)
7. H. Van Vlierberghe, M. De Vos, M. Hautekeete, A. Elewaut. Severe complications following endoscopic variceal ligation : should EVL be avoided in Child C patients ? Acta Gastro-enterologica Belgica 1999 ; 62 : 175-177. (Impact factor: 0.83)
8. S. Depraetere, E. Van Kerschaever, H. Van Vlierberghe, A. Elewaut, J. Brouwer, H. Niesters, S.

- Schalm, G. Maertens, G. Leroux-Roels. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. *Journal of Medical Virology* 2000 ; 60 : 126-132. (Impact factor: 2.7)
9. K.J.Mortelé, M.Praet, H.Van Vlierberghe, M.Kunnen, P.R.Ros. CT and MR imaging findings in focal nodular hyperplasia of the liver: radiologic-pathologic correlation. *American Journal of Radiology* 175, September 2000: 687-692. (Impact factor: 2.9)
10. V.Meersschaut, K.J.Mortelé, R.Troisi, H.Van Vlierberghe, M.De Vos, L.Defreyne, B.de Hemptinne, M.Kunnen. Value of MR cholangiography in the evaluation of postoperative biliary complications following orthotopic liver transplantation. *European Radiology* 2000, 10: 1576-1581. (Impact factor: 3.6)
11. H. Van Vlierberghe, L. Messiaen, M. Hautekeete, A. De Paepe. Prevalence of the Cys282Tyr and His63Asp mutation in Flemish patients with hereditary hemochromatosis. *Acta Gastro-enterologica Belgica* 2000; 63: 250-253. (Impact factor: 0.83)
12. Dixon J, Delwaide J, Horsmans Y, Van Vlierberghe H. Chronic hepatitis B therapy with lamivudine in clinical practice. Summary of the discussion. *Acta Gastro-enterologica Belgica*; 63(4): 357-358, 2000. (Impact factor: 0.83)
13. I.Colle, H.Van Vlierberghe, R.Troisi, B.de Hemptinne, M.De Vos. Living related adult-to-adult liver transplantation: which patient should benefit from this technique? *Acta Gastro-enterologica Belgica* 2001, 64: 1-3. (Impact factor: 0.83)
14. H. Van Vlierberghe, M.Dhont, H.Verdievel, M.De Vos, A.Elewaut. Influence of the intake of low oral contraceptives, alcohol and grapefruit in the results of the C13 aminopyrin breath test. *Digestive Diseases and Sciences*, 46(1), 133-139, January 2001. (Impact factor: 1.7)
15. R.Troisi, I.Colle, H.Van Vlierberghe, U.J.Hesse, O.Cuomo, B.de Hemptinne. Splenectomy and liver transplantation. *Transplant Proceedings*, vol 33, No 1-2, 2001. (Impact factor: 1.0)
16. H.Van Vlierberghe, J.R.Delanghe, M.De Vos, G.Leroux-Roels and the BASL. Factors influencing ribavirin induced anemia. *Journal of Hepatology* , 34(6), 911-916, 2001. (Impact factor: 7.1)
17. Mortelet KJ, De Keukeleire K, Praet M, Van Vlierberghe H, de Hemptinne B, Ros PR. Malignant focal hepatic lesions complicating underlying liver disease: dual-phase contrast-enhanced spiral CT sensitivity and specificity in orthotopic liver transplant patients. *Eur Radiol* 2001; 11(9): 1631-8. (Impact factor: 3.6)
18. H. Van Vlierberghe, J.R. Delanghe, S.De Bie, M. Praet, A. De Paepe, L. Messiaen, M. De Vos, G. Leroux-Roels. Association between Cys282Tyr missense mutation and haptoglobine phenotype polymorphism in patients with chronic hepatitis C. *European Journal of Gastroenterology and Hepatology* 2001, 13: 1077-1081. (Impact factor: 2.3)
19. B.Brans, F. De Winter, L.Defreyne, R.Troisi, P.Vanlangenhove, H.Van Vlierberghe, B.Lambert, M.Praet, B.de Hemptinne, RA Dierckx. The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study. *Cancer Biother Radiopharm* 2001; 16(4): 333-338. (Impact factor: 1.6)
20. S.De Coninck, H.Van Vlierberghe, M.De Vos, A.Elewaut. Review: hepatopulmonary syndrome and portopulmonary hypertension. *Acta Gastroenterol Belg* 2001; 64(3): 286-294. (Impact factor: 0.83)
21. H.Van Vlierberghe, M.Langlois, J.Delanghe, Y. Horsmans, P.Michielsen, J.Henrion, R. Cartuyvels, J.Billiet, M.De Vos, G.Leroux-Roels. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. *Journal of Hepatology* 2001; 35(6): 707-711. (Impact factor: 7.1)
22. R.Schoonjans, B.Van Vlem, W.Vandamme, H.Van Vlierberghe, N.Van Heddeghem, W.Van Biesen, A.Mast, R.Vanholder, N.Lameire, M.De Vos. Gastric emptying of solids in cirrhotic and peritoneal dialysis patients: influence of peritoneal volume load. *Eur J Gastroenterol Hepatol* 2002; 14(4): 395-398. (Impact factor: 2.3)
23. B.Brans, K.Van Laere, F.Gemmel, L.Defreyne, P.Vanlangenhove, R.Troisi, H.Van Vlierberghe, I.Colle, B.de Hemptinne, R.A.Dierckx. Combining iodine-131-lipiodol therapy with low-dose cisplatin as radiosensitizer: preliminary results in hepatocellular carcinoma. *Eur J Nucl Med* 2002; 29: 928-932. (Impact factor: 4.6)
24. M.Adler, P.Goubau, F.Nevens, H.Van Vlierberghe. Hepatitis C virus: the burden of the disease. *Acta Gastroenterol Belg* 2002; 65(2): 83-86. (Impact factor: 0.83)

25. H.Van Vlierberghe, I.Colle, R.Troisi, B.de Hemptinne, M.De Vos. Liver transplantation and mental retardation. *Acta Gastroenterologica Belg* 2002; 65(2): 131-132. (Impact factor: 0.83)
26. K.J.Mortelé, H.Van Vlierberghe, W.Wiesner, P.R.Ros. Hepatic veno-occlusive disease: MRI findings. *Abdom Imaging* 2002, 27(5): 523-526. (Impact factor: 1.6)
27. R.Troisi, G.Militerno, E.Hoste, J.Decruyenaere, K.Colpaert, K.Monsieurs, I.Colle, H.Van Vlierberghe, B.de Hemptinne. Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults? *Transplantation Proceedings* 2002; 34(5): 1531. (Impact factor: 1.0)
28. H.Van Vlierberghe, H.Verdievel, I.Colle, J.Delanghe, D.Bernard, M.Praet, G.Leroux-Roels, M.De Vos. Non-transferrin-bound iron (NTBI) in untreated and ribavirin treated chronic hepatitis C patients. *Alimentary Pharmacology and Therapeutics* 2002; 16: 1555-1562. (Impact factor: 3.8)
29. I.Colle, H.Van Vlierberghe, R.Troisi, K.De Ridder, D.Benoit, B.de Hemptinne, M.De Vos. *Campylobacter*-associated Guillain-Barré syndrome after orthotopic liver transplantation for hepatitis C cirrhosis: a case report. *Hepatology Research* 2002; 24:205-211. (Impact factor: 1.6)
30. B.Brans, B.Lambert, De Beule E, F.De Winter, S.Van Belle, H.Van Vlierberghe, B.de Hemptinne, R.A.Dierckx. Quality of life assessment in radionuclide therapy: a feasibility study of the EORTC QLQ-C30 questionnaire in palliative I-131-Lipiodol therapy. *Eur J Nucl Med Molec Imag* 2002; 29(10):1374-1379. (Impact factor: 4.6)
31. KJ Mortelé, M.Praet, H.Van Vlierberghe, B.de Hemptinne, K.Zou, PR Ros. Focal nodular hyperplasia of the liver: detection and characterization with plain and dynamic-enhanced MRI. *Abdom Imaging* 2002; 27(6): 700-707. (Impact factor: 1.6)
32. L, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, DeHertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. *Gastroenterology* 2002; 123: 1831-1838. (Impact factor: 12.7)
33. I.Colle, H.Van Vlierberghe, R.Brenard, R.Troisi, B.de Hemptinne, B.Navez, S.De Coninck, M.De Vos. Biliary complications of large echinococcus granulosus cysts: report of 2 cases and review of the literature. *Acta Clinica Belgica*, 2002; 57(6): 351-356. (Impact factor: 1.2)
34. P.Michielsen, R.Brenard, N.Bourgeois, C.de Galocsy, J.Delwaide, J.Henrion, Y.Horsmans, F.Nevens, H.Reynaert, G.Robaey, D.Sprengers, H.Van Vlierberghe. Hepatitis C: screening, treatment and prevention. Practical guidelines. *Acta Gastroenterologica Belgica* 2003; 66: 15-19. (Impact factor: 0.83)
35. R.Troisi, G.Cammu, G.Militerno, L.De Baerdemaeker, J.Decruyenaere, E.Hoste, P.Smeets, I.Colle, H.Van Vlierberghe, M.Petrovic, D.Voet, E.Mortier, U.J.Hesse, B.de Hemptinne. Modulation of portal graft inflow: a necessity in adult living-donor transplantation? *Annals of Surgery* 2003; 237(3): 429-436. (Impact factor: 9.7)
36. I.Colle, H.Van Vlierberghe, P.Pattyn, R.Troisi, D.Vogelaers, B.de Hemptinne, M. De Vos. Cholestasis as presenting symptom of portal cavernoma. *Hepatology Research* 2003; 25: 32-37. (Impact factor: 1.6)
37. H.Van Vlierberghe, J.Delanghe. Haptoglobin polymorphism and iron hemostasis. *Clinical Chemistry* 2003; 49(4): 708-709. (Impact factor: 6.1)
38. I.Colle, H.Van Vlierberghe. Diagnosis and therapeutic problems of primary sclerosing cholangitis. *Acta Gastroenterologica Belgica* 2003; 66(2): 155-159. (Impact factor: 0.83)
39. S.Steyaert, P.Vanlandschoot, H.Van Vlierberghe, H.Diepolder, G.Leroux-Roels. Soluble CD14 levels are increased and inversely correlated with the levels of hepatitis B surface antigen in chronic hepatitis B patients. *Journal of Medical Virology* 2003; 71(2): 188-194. (Impact factor: 2.7)
40. H.Van Vlierberghe. NASH/NAFLD management. Summary of the discussion. *Acta Gastroenterologica Belgica* 2003; 66: 154. (Impact factor: 0.83)
41. H.Van Vlierberghe, G.Leroux-Roels, M.Adler, N.Bourgeois, F.Nevens, Y.Horsmans, J.Brouwer, I.Colle, J.Delwaide, R.Brenard, B.Bastens, J.Henrion, R.A. de Vries, C.de Galocsy, P.Michielsen, G.Robaey, L.Bruckers. Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A controlled multicenter randomised trial. *Journal of Viral Hepatitis* 2003; 10: 640-466. (Impact factor: 3.4)
42. F.Nevens, T.Roskams, H.Van Vlierberghe, Y.Horsmans, D.Sprengers, A.Elewaut, V.Desmet, G.Leroux-Roels, E.Quinaux, E.Depla, S.Dincq, C.Vander Stichele, G.Maertens, F.Hulstaert. Improvement in liver histology and serum ALT is associated with immune response to envelope

- protein E1 therapeutic vaccination in 24 patients with chronic hepatitis C. *Hepatology* 2003; 38: 1289-1296. (Impact factor: 11.6)
43. I.Colle, D.Schoors, H.Van Vlierberghe, G.Van Maele, M.De Vos, H.Reynaert. Influence of posture on haemodynamics, sodium and hormonal homeostasis in cirrhotic patients with and without ascites. *Acta Gastroenterologica Belgica* 2003; 66: 206-212. (Impact factor: 0.83)
44. F.Gemmel, M.Ravier, R.Troisi, H.Van Vlierberghe, B.Lambert, V.Renard, RA Dierckx. Radionuclide detection of peritoneovenous shunt patency. *Clin Nucl Med* 2003; 28(12): 986-987. (Impact factor: 3.2)
45. H.Van Vlierberghe, R.Troisi, I.Colle, S.Ricciardi, M.Praet, B.de Hemptinne. Hepatitis C infection (HCV) related liver disease: patterns of recurrence and outcome in cadaveric and living donor liver transplantation in adults. *Transplantation* 2004; 77(2): 210-214. (Impact factor: 3.8)
46. M.R.Langlois, M.L.De Buyzere, H.Van Vlierberghe, J.R.Delanghe. Haptoglobin polymorphism and serum ferritin concentration in ageing subjects. *Br J Haematol* 2004; 124: 555-556. (Impact factor: 4.4)
47. H.Van Vlierberghe, I.Borbath, J.Delwaide, J.Henrion, P.Michielsen, C.Verslype and the BASL steering committee. BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma. *Acta Gastroenterologica Belgica* 2004; 67(1): 14-25. (Impact factor: 0.83)
48. T.Bosman, K.Vonck, P.Claeys, H.Van Vlierberghe, M.De Clercq, J. De Reuck, P.Boon. Enterocolitis: an adverse event in refractory epilepsy patients treated with levetiracetam? *Seizure* 2004; 13: 76-81. (Impact factor: 2.1)
49. I.Colle, A.S.De Vriese, H.Van Vlierberghe, N.H.Lameire, M.De Vos. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. *Liver International* 2004; 24: 63-68. (Impact factor: 2.9)
50. N.Callewaert, H.Van Vlierberghe, A.Van Hecke, W.Laroy, J.Delanghe, R.Contreras. Noninvasive diagnosis of liver cirrhosis using DNA-sequencer-based total serum protein glycomics. *Nature Medicine* 2004; vol 10, Nr 4: 429-434. (Impact factor: 28.9)
51. J.T.Brouwer, F.Nevens, F.C.Bekkerering, N.Bourgeois, H.Van Vlierberghe, C.J.Weegink, V.Lefebvre, J.van Hattum, J.Henrion, J.Delwaide, B.E.Hansen, S.W.Schalm. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. *Journal of Hepatology* 2004; 40: 689-695. (Impact factor: 7.1)
52. I.Colle, A.De Vriese, H.Van Vlierberghe, N.Lameire, M.De Vos. Vascular hyporesponsiveness in the mesenteric artery of anesthetised rats with cirrhosis and portal hypertension. *European Journal of Gastroenterology and Hepatology* 2004; 16(2): 139-145. (Impact factor: 2.3)
53. H.Van Vlierberghe, M.Langlois, J.Delanghe. Haptoglobin polymorphism and iron homeostasis in health and in disease. *Clinica Chimica Acta* 2004; 345(1-2): 35-42. (Impact factor: 2.9)
54. J.Delwaide, N.Bourgeois, C.Gerard, D.De Maeght, F.Mokaddem, E.Wain, B.Bastens, J.Fevry, M.Gehenot, O.Le Moine, J.P.Martinet, G.Robaey, B.Servais, M.Van Gossom, H.Van Vlierberghe and the BASL. Treatment of acute hepatitis C with interferon alpha 2b: early initiation of treatment is the most effective predictive factor of sustained viral response. *Alimentary Pharmacology and Therapeutics* 2004; 20(1): 15-22. (Impact factor: 3.8)
55. V.Donckier, R.Troisi, M.Toungouz, I.Colle, H.Van Vlierberghe, C.Jacquy, P.Martiat, P.Stordeur, L.Zhou, N.Boon, M.Lambermont, L.Schandené, J.L.Van Laethem, L.Noens, M.Gelin, B.de Hemptinne, M.Goldman. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. *Transplant Immunology* 2004; 13(2): 139-46. (Impact factor: 2.1)
56. I.Colle, H.Van Vlierberghe, R.Troisi, B.de Hemptinne. Transplanted liver: consequences of denervation for liver functions. *Anat Rec* 2004; 280A(1): 924. (Impact factor: 2.0)
57. B.Lambert, K.Bacher, L.Defreyne, F.Gemmel, H.Van Vlierberghe, JM Jeong, RA Dierckx, C.Van de Wiele, H.Thierens, F.De Vos. 188Re-HDD/Lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. *Journal of Nuclear Medicine* 2005; 46: 60-66. (Impact factor: 6.6)
58. Lambert B, Praet M, Vanlangenhove P, Troisi R, Hemptinne B, Gemmel F, Van Vlierberghe H, Van de Wiele C. Radiolabeled lipiodol therapy for hepatocellular carcinoma in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome. *Cancer Biother Radiopharm.* 2005 Apr;20(2):209-14. (Impact factor: 1.6)
59. R.Troisi, S.Ricciardi, P.Smeets, M.Petrovic, G.Van Maele, I.Colle, H.Van Vlierberghe, B.de Hemptinne. Effects of hemi-portocaval shunts for inflow modulation in the outcome of small-for-size grafts in living donor liver transplantation. *American Journal of Transplantation.* 2005; 5: 1397-1404. (Impact factor: 6.5)

60. T.Botelberge, H.Van Vlierberghe, D.Voet, L.Defreyne. Detachable balloon embolization of an arterioportal fistula following liver biopsy in a liver transplant recipient: a case report and review of the literature. *Cardiovascular and Interventional Radiology* 2005; 28: 1-5. (Impact factor: 1.7)
61. I.Desombere, H.Van Vlierberghe, S.Couvent, F.Clinckspoor, G.Leroux-Roels. Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections. *J. Clinical Microbiology* 2005; 43(6):2590-2597. (Impact factor: 3.9)
62. E.Nagler, H.Van Vlierberghe, I.Colle, R.Troisi, B.de Hemptinne. Impact of MELD on short-term and long-term outcome following liver transplantation: a European perspective. *Eur J Gastroenterol Hepatol.* 2005 Aug;17(8):849-56. (Impact factor: 2.3)
63. Hutse V, Verhaegen E, De Cock L, Quoilin S, Vandenberghe H, Horsmans Y, Michiels P, Van Damme P, Van Vlierberghe H, Claeys F, Vranckx R, Van Oyen H. Oral fluid as a medium for the detection of hepatitis B surface antigen. *J Med Virol.* 2005 Jul 19;77(1):53-56. (Impact factor: 2.7)
64. S.Ricciardi, D.Vogelaers, F.Van Wanzeele, I.Colle, H.Van Vlierberghe, B.de Hemptinne, R.Troisi. Specific problems in a HIV positive patient with end-stage alcoholic liver disease after liver transplantation: infections and immunosuppression. *Transplantationsmedizin* 2005; 17: 42-49. (Impact factor:)
65. Lambert B, Bacher K, Defreyne L, Van Vlierberghe H, Jeong JM, Wang RF, van Meerbeeck J, Smeets P, Troisi R, Thierens H, De Vos F, Van de Wiele C. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. *Eur J Nucl Med Mol Imaging.* 2005 Dec 7 (Epub). (Impact factor: 4.6)
66. Van Vlierberghe H, Colle I, Henrion J, Michiels P, Delwaide J, Reynaert H, Borbath I, Martinet JP, Sprengers D, Brenard R; Belgian Association for the Study of the Liver steering committee. The HepCar registry: report on a one-year registration program of hepatocellular carcinoma (HCC) in Belgium. What is daily practice in HCC? *Acta Gastroenterol Belg.* 2005 Oct-Dec;68(4):403-11. (Impact factor: 0.83)
67. G.Robaey, H.Van Vlierberghe, C.Matheï, M.Van Ranst, L.Bruckers, F.Buntinx on behalf of the members of the BASL steering committee and the Benelux Study Group. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. *Eur J Gastroenterol Hepatol* 2006; 18(2): 159-166. (Impact factor: 2.3)
68. Anja M. Geerts, An S. De Vriese, Eline Vanheule, Hans Van Vlierberghe, Siska Mortier, Kin-Jip Cheung, Pieter Demetter, Norbert Lameire, Martine De Vos, Isabelle Colle. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. *Liver International*; Volume 26, Issue 7, 2006Sep1, Page 889-898. (Impact factor: 2.9)
69. Reynaert H, Van Vlierberghe H, De Beeck BO, Roskams T. Management of small focal liver lesions in a cirrhotic liver: discussion. *Acta Gastroenterol Belg.* 2006 Apr-Jun;69(2):236-7. (Impact factor: 0.83)
70. Donckier V, Troisi R, Le Moine A, Toungouz M, Ricciardi S, Colle I, Van Vlierberghe H, Craciun L, Libin M, Praet M, Noens L, Stordeur P, Andrien M, Lambermont M, Gelin M, Bourgeois N, Adler M, de Hemptinne B, Goldman M. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. *Liver Transpl.* 2006 Sep 26;12(10):1523-1528. (Impact factor: 4.4)
71. Anja M.Geerts, Kin-Jip Cheung, Hans Van Vlierberghe, An S. De Vriese, Siska Mortier, Eline Vanheule, Norbert Lameire, Martine De Vos, Isabelle Colle. Decreased leukocyte recruitment in the mesenteric microcirculation of rats with cirrhosis is partially restored by treatment with peginterferon: an in vivo study. *J Hepatol*; 2007, 46(5):804-15. (Impact factor: 7.1)
72. Desombere I, Van Vlierberghe H, Weiland O, Hultgren C, Sallberg M, Quiroga J, Carreno V, Leroux-Roels G. Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. *J Med Virol.* 2007 Apr 24;79(6):701-713. (Impact factor: 2.6)
73. I.Colle, C.Van Steenkiste, A.Geerts, H.Van Vlierberghe. Hepatopulmonary syndrome and portopulmonary hypertension: whats news. *Acta Gastroenterologica Belgica*; Vol LXX, Apr-June 2007, 203-209. (Impact factor: 0.83)
74. I.Colle, van Onna, F.Berrepoet, H.Van Vlierberghe, A.Geerts, R.Troisi, B.de Hemptinne. One-sided limb lymphedema in a liver transplant recipient receiving Sirolimus. *Acta Gastroenterologica Belgica.* Vol 70, Fasc. 2 of 3, 2007. (Impact factor: 0.83)
75. Veldt BJ, van der Vliet HJ, von Blomberg BM, van Vlierberghe H, Gerken G, Nishi N, Hayashi K,

- Scheper RJ, de Kneegt RJ, van den Eertwegh AJ, Janssen HL, van Nieuwkerk CM. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. *J Hepatol.* 2007 47(3): 356-65. (Impact factor: 7.1)
76. Troisi R, Montalti R, Smeets P, Van Huysse J, Van Vlierberghe H, Colle I, De Gendt S, de Hemptinne B. The value of laparoscopic liver surgery for solid benign hepatic tumors. *Surg Endosc.* 2007 Aug 21; [Epub ahead of print] (Impact factor: 3.2)
77. Dezza MC, Berrevoet F, Sainz-Barriga M, Rossetto A, Colenbie L, Haentjens I, Van Vlierberghe H, Colle I, Van Huysse J, Praet M, Rogiers X, de Hemptinne B, Troisi R. The choice of recipient does not have a bearing on early outcome in liver transplant patients receiving grafts from non-heart-beating donors: a reappraisal? *Transplant Proc.* 2007 Oct;39(8):2675-7. (Impact factor: 1.0)
78. Craciun L, Stordeur P, Troisi R, Le Moine A, Toungouz M, Colle I, Van Vlierberghe H, Loi P, Lucidi V, Praet M, de Hemptinne B, Goldman M, Donckier V.
79. A rapid test of alloreactivity based on interleukin-2 mRNA expression might identify liver transplant recipients with donor-specific hyporesponsiveness. *Transplant Proc.* 2007 Oct;39(8):2665-7. (Impact factor: 1.0)
80. H. Van Vlierberghe. The hepatitis C virus burden: a Dutch point of view. *Netherlands Journal of Medicine* January 2008, Vol 66, No.1, p 1-2. (Impact factor: 1.5)
81. E. Vanheule, A.M. Geerts, H. Reynaert, H. Van Vlierberghe, A. Geerts, M. De Vos, I. Colle. Influence of somatostatin and octreotide on liver microcirculation in an experimental mouse model of cirrhosis studied by intravital fluorescence microscopy. *Liver International* 2008, 28(1): p.107-116. (Impact factor: 2.9)
82. Urbain D, Vandebosch S, Hindryckx P, Colle I, Reynaert H, Mana F, Vanden Branden S, Van Vlierberghe H, De Vos M, De Looze D. Capsule endoscopy findings in cirrhosis with portal hypertension: A prospective study. *Dig Liver Dis.* 2008 Feb 19. (Impact factor: 2.5)
83. M. Sainz-Barriga, S. Ricciardi, I. Haentjens, L. Colenbie, I. Colle, H. Van Vlierberghe, B. de Hemptinne, R. Troisi. Split liver transplantation with extended right grafts under patient-oriented allocation policy. Single center matched-pair outcome analysis. *Clin Transplantation*, 2008, Mar (3). (Impact factor: 2.3)
84. Michael Adler, Filip De Pauw, Pierre Vereerstraeten, Agnese Fancello, Jan Lerut, Peter Starkel, Hans Van Vlierberghe, Roberto Troisi, Vincent Donckier, Olivier Detry, Jean Delwaide, Peter Michielsen, Thierry Chapelle, Jacques Pirenne, and Frederik Nevens. Outcome of Patients with Hepatocellular Carcinoma Listed for Liver Transplantation Within the Eurotransplant Allocation System. *Liver Transplantation* 14:526-533, 2008. (Impact factor: 4.4)
85. K.J. Cheung, K. Tilleman, I. Colle, D. Deforce, H. Van Vlierberghe. Serum proteomics and liver fibrosis. *Eur J Gastroenterol Hepatol.* 2008 May;20(5):450-64. (Impact factor: 2.3)
86. Colle I, Geerts AM, Van Steenkiste C, Van Vlierberghe H. Hemodynamic Changes in Splanchnic Blood Vessels in Portal Hypertension. *Anat Rec (Hoboken).* 2008 May 16;291(6):699-713. (Impact factor: 2.0)
87. Geerts AM, Vanheule E, Van Vlierberghe H, Leybaert L, Van Steenkiste C, De Vos M, Colle I. Rapamycin prevents mesenteric neo-angiogenesis and reduces splanchnic blood flow in portal hypertensive mice. *Hepatol Res.* 2008; 38: 1130-1139. (Impact factor: 1.6)
88. I. Colle, K. De Keukeleire, W. Pauwels, H. Van Vlierberghe. Hepatic encephalopathy because of spontaneous mesenterico-caval shunt. *Liver International*, 28(7) p 982, 2008. (Impact factor: 2.9)
89. A. Geerts, E. Vanheule, M. Praet, H. Van Vlierberghe, M. De Vos, I. Colle. Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation. *Int J Exp Pathol* 2008; 89: 251-263. (Impact factor: 2.3)
90. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Pallota MG, Zarba JJ, Boyer M, Riordan S, Strickland A, Tebbutt N, Thomson B, Borbath I, De Greve J, Van Laethem JL, Van Steenberghe W, Van Vlierberghe H, Barrios C, Cosme de Oliveira A, Kotzev I, Takov D, Tchernev K, Burak K, Ma M, Metrakos P, Olweny C, Sherman M, Gamargo Garate C, Martinez-Castillo J, Beaugrand M, Bennisouna J, Blanc JF, Bronowicki JP, Degos F, Dominguez S, Grange JD, Hillon P, Raoul JL, Seitz JF, Blum H, Buggisch P, Caspary W, Dollinger M, Galle PR, Gerken G, Göke B, Gregor M, Greten T, Häussinger D, Scherübl J, Scheulen M, Schmid R, Spengler U, Wiest R,

Zeuzem S, Arvanitakis C, Germanidis G, Katsos I, Figer A, Stemmer S, Amadori D, Bolondi L, Cognetti F, Craxi A, Farinati F, Gridelli C, Martoni A, Mazzaferro V, Porta C, Ricci S, Sangiovanni A, Santoro A, Trevisani F, Cisnero Garza LE, Gane E, O'Donnell A, Leon J, Lozano A, Jassem J, Ryzewska G, Szawlowski A, Tomczak P, Badulescu F, Miron L, Kubyshev V, Bruix J, Forner A, Bustamante Schneider J, Diago M, Montero Alvarez JL, Pascual S, Ruiz del Arbol L, Sangro B, Solá R, Taberero J, Muellhaupt B, Roth A, Jeffrey Evans TR, Falk S, Meyer T, Reeves H, Ross P, Befeler A, Boyer T, Britten C, Byrne T, Garcia-Tsao G, Gold P, Goldenberg A, Heuman D, Kennedy P, Koch A, Llovet JM, Marrero J, Schilsky M, Schwartz J, Schwartz M. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med.* 2008 Jul 24;359(4):378-90. (Impact factor: 50)

91. Eline Vanheule, Anja M. Geerts, Jacques Van Huisse, Daphne Schelfhout, Marleen Praet, Hans Van Vlierberghe, Martine De Vos and Isabelle Colle. An intravital microscopic study of the hepatic microcirculation in cirrhotic mice models: relationship between fibrosis and angiogenesis. *Int. J. Exp. Path.* (2008), 89, 419432. (Impact factor: 2.3)

92. Y.Horsmans, I.Colle, H.Van Vlierberghe, P.Langlet, M.Adler, N.Bourgeois, R.Brenard, P.Michielsen, A.Goossens, L.Bruckers. Weekly pegylated interferon alfa 2b versus daily interferon alfa 2b versus standard regiment of interferon alfa 2b in the treatment of patients with chronic hepatitis C virus infection. *Acta Gastroenterol Belgica* 2008, 71: 293-297. (Impact factor: 0.83)

93. Chen C, Schmilovitz-Weiss H, Liu XE, Pappo O, Halpern M, Sulkes J, Braun M, Cohen M, Barak N, Tur-Kaspa R, Vanhooren V, Van Vlierberghe H, Libert C, Contreras R, Ben-Ari Z. Serum Protein N-Glycans Profiling for the Discovery of Potential Biomarkers for Nonalcoholic Steatohepatitis. *J Proteome Res.* 2009 Jan 13. (Impact factor: 5.7)

94. Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. Alteration of protein glycosylation in liver diseases. *J. Hepatol.* 2009 Mar;50(3):592-603. (Impact factor: 7.1)

95. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. *J Viral Hepat.* 2009 Feb 15. [Epub ahead of print] (Impact factor: 3.3)

96. V.Donckier, A.SAnchez-Fueyo, L.Craciun, V.Lucidi, A.Buggenhout, R.Troisi, X.Rogiers, N.Bourgeois, N.Boon, C.Moreno, I.Colle, H.Van Vlierberghe, B.de Hemptinne. M.Goldman. Induction of tolerance in solid organ transplantation: the rationale to develop clinical protocols in liver transplantation. *Transplantation Proceedings* 2009, 41(2): 603-606. (Impact factor: 1.0)

97. Donckier V, Craciun L, Lucidi V, Buggenhout A, Troisi R, Rogiers X, Boon N, Gustot T, Moreno C, Bourgeois N, Colle I, Van Vlierberghe H, Nagy N, Praet M, Dernies T, Amrani M, Stordeur P, de Hemptinne B, Goldman M. Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cells. *Transplantation.* 2009 May 15;87(9 Suppl):S91-5. (Impact factor: 3.8)

98. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçalves F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; Epic Study Group. Alberti A, Perez Alvarez R, Anderson F, Balart L, Barange K, Berg T, Bodenheimer H, Bourliere M, Bronowicki JP, Brunner H, Buggisch P, Burak KW, Calleja JL, Carrilho F, Carvalho A, Caselmann W, Causse X, Cheng W, Coelho HS, Colombato L, Crawford D, Craxi A, Curciarello J, Delwaide J, Serra Desfilis MA, Diago M, Dusheiko G, Enns R, Esteban-Mur R, Fainboim H, Feinman SV, Ferraz ML, Flamm S, Ferreira Filho RP, Focaccia R, Gadano A, George J, Goncales FL, Gordon S, Gutfreund KS, Haussinger D, Heathcote EJ, Hilzenrat N, Hinrichsen H, Horsmans Y, Hultcrantz R, Jacobson I, Jeffrey G, Kaita K, King P, Kwo P, Lai MY, Leggett B, Lyra L, Maieron A, Manesis EK, Manns M, Marcellin P, Marotta P, Marsano L, Mattos A, Mauad M, McCullough AJ, McGarrity T, McHutchison J, Brandao Mello C, Millison L, Moreno-Otero R, Muellhaupt B, Muzzillo DA, Ngu M, Niederau C, Pauly MP, Peltekian K, Perrillo R, Picciotto A, Pinchuk L, Podda M, Poo JL, Poordad F, Poupon R, Poynard T, Ramos-Gomez M, Reichen J, Reindollar R, Reymunde A, Rizzetto M, Roberts S, Rosa H, Rosenberg W, Routley D, Rumi MG, Rustgi V, Sanchez-Tapias J, Schiff E, Schmidt W, Schmidt W, Shaikh OS, Sherman K, Sievert W, Silva M, Smith C, Spengler U, Sulkowski M, Tanno H, Teixeira R, Terg R, Toro D, Torres E, Castellanos Tortajada G, Tran A, Trepo C, Tsai N, Vale AM, Varon A, Planas Vila R, Villa E, Van Vlierberghe H, Wong F, Zchoval R, Zeuzem S, Zignego AL. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. *Gastroenterology.* 2009 May;136(5):1618-28. (Impact factor: 12.7)

99. P. Langlet, F. D'Heygere, J. Henrion, M. Adler, J. Delwaide, H. Van Vlierberghe, J. P. Mulkay, L.

- Lasser, R. Brenard, Y. Horsmans, P. Michielsens, A. Laureys, F. Nevens. Clinical trial: a randomized trial of pegylated-interferon--2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients. *Alimentary Pharmacology & Therapeutics* 2009, Volume 30 Issue 4, Pages 352-363. (Impact factor: 3.8)
100. F.Heindryckx, I.Colle, H.Van Vlierberghe. Experimental mouse models for hepatocellular carcinoma research. *Int J Exp Path* 2009; 90(4): 367-386. (Impact factor: 2.3)
101. Vanderschaeghe D, Debruyne E, Van Vlierberghe H, Callewaert N, Delanghe J. Analysis of gamma-globulin mobility on routine clinical CE equipment: exploring its molecular basis and potential utility. *Electrophoresis* 2009 Jul 20;30(15):2617-2623. (Impact factor: 3.5)
102. Van Steenkiste C, Geerts A, Vanheule E, Van Vlierberghe H, De Vos F, Olievier K, Casteleyn C, Laukens D, De Vos M, Stassen JM, Carmeliet P, Colle I. Role of Placental Growth Factor in Mesenteric Neo-Angiogenesis in a Mouse Model of Portal Hypertension. *Gastroenterology*. 2009 Vol 137, issue 6, 2112-2114. (Impact factor: 12.7)
103. Vandecasteele E, De Waele J, Vandijck D, Blot S, Vogelaers D, Rogiers X, Van Vlierberghe H, Decruyenaere J, Hoste E. Antimicrobial prophylaxis in liver transplant patients - a multicenter survey endorsed by the European Liver and Intestine Transplant Association. *Transpl Int*. 2009 Sep 29. [Epub ahead of print]. (Impact factor: 3.1)
104. Decoster EL, Troisi R, Sainz-Barriga M, Haentjens I, Colenbie L, Geerts A, Colle I, Van Vlierberghe H, de Hemptinne B, Rogiers X. Improved Results for Adult Split Liver Transplantation With Extended Right Lobe Grafts: Could We Enhance Its Application? *Transplant Proc*. 2009 Oct;41(8):3403-3406. (Impact factor: 1.0)
105. P.Michielsens, E.Bottieau, H.Van Vlierberghe, E.Van Marck, E.Vandemaele, M.Denys, J.P.Brasseur, M.Popan and the BASL steering committee. Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alfa-2b plus ribavirin: a multi-centred Belgian study. *Acta Gastroenterologica Belgica* 2009, vol 72, Fasc 4, 389-393. (Impact factor: 0.83)
106. Bram Blomme, Christophe Van Steenkiste, Jacques Vanhuysse, Isabelle Colle, Nico Callewaert, Hans Van Vlierberghe. The impact of elevation of total bilirubin level and etiology of the liver disease on serum N-glycosylation patterns in mice and men. *American Journal of Physiology - Gastrointestinal and Liver Physiology* 2010 Jan 7. [Epub ahead of print] (Impact factor: 3.6)
107. Kin Jip Cheung, Louis Libbrecht, Kelly Tilleman, Dieter Deforce, Isabelle Colle, Hans Van Vlierberghe. Galectin-3-Binding Protein: A Serological and Histological Assessment in Accordance with Hepatitis C-related Liver Fibrosis. *European J Gastroenterology and Hepatology* 2010 Feb 24. [Epub ahead of print]. (Impact factor: 2.1)
108. H.Van Vlierberghe, M.Adler, B.Bastens, I.Colle, J.Delwaide, J.Henrion, Y.Horsmans, P.Michielsens, P.Golstein, J.P.Mulkay, W.Van Steenberghe, P.Yap, F.Nevens, AM Denys, J.P.Brasseur. Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the Pegintrust Study. *Acta Gastroenterologica Belgica* 2010; vol73(fasc1): 5-11. (impact factor 0.83)
109. Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. *European J Gastroenterology and Hepatology* 2010; Volume 22(Issue 4): pp 494-499. (Impact factor: 2.1)
110. Debruyne EN, Vanderschaeghe D, Van Vlierberghe H, Vanhecke A, Callewaert N, Delanghe JR. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. *Clin Chem* 2010; Mar 26. [Epub ahead of print] (Impact factor: 5.6)
111. De Bus L, Depuydt P, Libbrecht L, Vandekerckhove L, Nollet J, Benoit D, Vogelaers D, Van Vlierberghe H. Severe Drug-induced Liver Injury Associated with Prolonged Use of Linezolid. *J Med Toxicol*. 2010 Apr 1. [Epub ahead of print] (Impact factor: 1.99)
112. Sara Van de Veire, Ingeborg Stalmans, Femke Heindryckx, Hajimu Oura, Annemiläi Tijeras-Raballand, Thomas Schmidt, Sonja Loges, Imke Albrecht, Bart Jonckx, Stefan Vinckier, Christophe Van Steenkiste, Sônia Tugues, Charlotte Rolny, Maria De Mol, Daniela Dettori,

Patricia Hainaud, Lieve Coenegrachts, Jean-Olivier Contreres, Tine Van Bergen, Henar Cuervo, Wei-Hong Xiao, Carole Le Henaff, Ian Buyschaert, Behzad Kharabi Masouleh, Anja Geerts, Tibor Schomber, Philippe Bonnin, Vincent Lambert, Jurgen Haustraete, Serena Zacchigna, Jean-Marie Rakic, Wladimiro Jiménez, Agnes Noël, Mauro Giacca, Isabelle Colle, Jean-Michel Foidar, Gerard Tobeles, Manuel Morales-Ruiz, José Vilar, Patrick Maxwell, Stanley A Vinores, Geert Carmeliet, Mieke Dewerchin, Lena Claesson-Welsh, Evelyne Dupuy, Hans Van Vlierberghe, Gerhard Christofori, Massimiliano Mazzone, Michael Detmar, Désiré Collen & Peter Carmeliet. Further pharmacological and genetic evidence for the efficacy of PIGF inhibition in cancer and ocular angiogenesis. *Cell* 141, 178190, April 2, 2010. (Impact factor: 31.2)

113. Cassiman D, Libbrecht L, Verslype C, Meersseman W, Troisi R, Zucman-Rossi J, Van Vlierberghe H. An adult male patient with multiple adenomas and a hepatocellular carcinoma: Mild Glycogen Storage Disease type Ia. *J Hepatol.* 2010 Volume 53, Issue 1, 213-217. (Impact factor: 7.1)

114. Van Steenkiste C, Staelens S, Deleye S, De Vos F, Vandenberghe S, Geerts A, Van De Wiele C, De Vos M, Van Vlierberghe H, Colle I. Measurement of porto-systemic shunting in mice by novel three-dimensional micro-single photon emission computed tomography imaging enabling longitudinal follow-up. *Liver Int.* 2010 May 23. [Epub ahead of print] (Impact factor: 2.9)

115. F. Nevens, H. Van Vlierberghe, F. D'Heygere, J. Delwaide, M. Adler, J. Henrion, A. Lenaerts, A. Hendlisz, P. Michielsens, B. Bastens, R. Brenard and the BERNAR 1 study Group. A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. *Acta Gastroenterologica Belgica* 2010; 73(2): 223-228 (Impact factor: 0.83).

116. Van Steenkiste C, Trachet B, Casteleyn C, van Loo D, Van Hoorebeke L, Segers P, Geerts A, Van Vlierberghe H, Colle I. Vascular corrosion casting: analyzing wall shear stress in the portal vein and vascular abnormalities in portal hypertensive and cirrhotic rodents. *Lab Invest.* 2010 Aug 16. [Epub ahead of print] (Impact factor: 4.6).

117. Heindryckx F, Mertens K, Charette N, Vandeghinste B, Casteleyn C, Van Steenkiste C, Slaets D, Libbrecht L, Staelens S, Starkel P, Geerts A, Colle I, Van Vlierberghe H. Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. *Mol Cancer.* 2010 Aug 20;9(1):219. [Epub ahead of print] (Impact factor: 4.16).

118. Van Laecke S, Desideri F, Geerts A, Van Vlierberghe H, Berrevoet F, Rogiers X, Troisi R, de Hemptinne B, Vanholder R, Colle I. Hypomagnesemia and the risk of new-onset diabetes after liver transplantation. *Liver Transpl.* 2010 Nov;16(11):1278-87. (Impact factor: 4.1).

119. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. *Liver International* 2010, november 15 [Epub ahead of print] (impact factor: 2.9).

120. Orlent Hans, Desombere Isabelle, Hansen Bettina, Van Vlierberghe Hans, Haagmans Bart, De Knecht Robert J., Schalm Solko W., Leroux-Roels Geert, Janssen, Harry L.A. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon/ribavirin combination therapy after 4 weeks of treatment. *European Journal of Gastroenterology & Hepatology.* 22(12):1443-1448, December 2010. (impact factor 1.6).

121. Scarinci A, Sainz-Barriga M, Berrevoet F, van den Bossche B, Colle I, Geerts A, Rogiers X, Van Vlierberghe H, de Hemptinne B, Troisi R. Early arterial revascularization after hepatic artery thrombosis may avoid graft loss and improve outcomes in adult liver transplantation. *Transplant Proc.* 2010 Dec;42(10):4403-8 (Impact factor: 1.0).

122. B. Lambert, H. Van Vlierberghe, R. Troisi, L. Defreyne. Radionuclide therapy for hepatocellular carcinoma. *Acta Gastroenterologica Belgica.* 2010; vol 73, Fasc 4, 484-488. (impact factor 0.83).

123. Blomme BA, Van Steenkiste C, Grassi P, Haslam SM, Dell A, Callewaert N, Van Vlierberghe H. Alterations of serum protein N-glycosylation in two mouse models of chronic liver disease are hepatocyte and not B-cell driven. *Am J Physiol Gastrointest Liver Physiol.* 2011 Feb 3. [Epub ahead of print] (impact factor : 3.6).

124. Desideri F, Marignani M, Vanovermeire O, Colle I, Delle Fave G, Hemelsoet D, Geerts A, Van Vlierberghe H. Moyamoya disease as a possible cause of neurological impairment following liver transplantation for Wilson's disease. *Hepatol Res.* 2011 Mar;41(3):282-6 (impact factor: 1.57).

125. Reinhart Speeckaert, Hans Van Vlierberghe, Roberto Troisi, Dirk De Bacquer, Marijn M. Speeckaert, Marc L. De Buyzere, Lutgarde Claeys, Bernard de Hemptinne and Joris R. Delanghe. Donor haptoglobin phenotype determines outcome following liver transplantation. *Transplantation International,* March 2011 (Epub) (impact factor: 3.2)

126. D'Heygere F, George C, Van Vlierberghe H, Decaestecker J, Nakad A, Adler M, Delwaide J, Laureys A, Nevens F. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis

C infected with genotype 5: A meta-analysis of two large prospective clinical trials. *J Med Virol.* 2011 May;83(5):815-9 (impact factor: 2.57).

127. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, Delwaide J, Horsmans Y, Van Vlierberghe H, Anderson F, Feinman SV, Heathcote J, Marotta P, Ramji A, Wong F, Peltakian K, Kaita K, Alric L, Ben Ali S, Bigard MA, Bourliere M, Boyer-Darrigrand N, Bronowicki JP, De Ledinghen V, Hezode C, Lebray P, Marcellin P, Maynard-Muet M, Pol S, Poynard T, Tran A, Trepo C, Truchi R, Vallet-Pichard A, Berg T, Guenther R, Lohse AW, Manns MP, Niederau C, Schmidt WE, Spengler U, Wedemeyer H, Zeuzem S, Carosi G, Colombo M, Craxi A, Rizzetto M, Zignego AL, Zuin M, Reymunde A, Buti Ferret M, Esteban R, Afdhal N, Bacon B, Balart L, Bennett M, Box T, Boyer T, Davis M, Flamm S, Freilich B, Galati J, Galler G, Gibas A, Godofsky E, Gordon S, Herrera J, Herrine S, Jacobson I, King J, Kwo P, Lawitz E, Lee W, Levin J, Luketic V, McCone J, McHutchison J, Mullen K, Morgan T, Muir A, Nunes F, Nyberg A, Nyberg L, Pauly MP, Peine C, Ravendhran N, Reindollar R, Riley T, Rossaro L, Rubin R, Ryan M, Schiff E, Sherman K, Shiffman M, Strauss R, Vierling J, Yapp R. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med.* 2011 Mar 31;364(13):1207-17. (impact factor: 50)

128. Christophe Van Steenkiste, Jordi Ribera, Anja Geerts, Montse Pauta, Sònia Tugues, Christophe Casteleyn, Louis Libbrecht, Kim Olievier, Ben Schroyen, Hendrik Reynaert, Leo A. van Grunsven, Bram Blomme, Stephanie Coulon, Femke Heindryckx, Martine De Vos, Jean Marie Stassen, Stefan Vinckier, Jose Altamirano, Ramón Bataller, Peter Carmeliet, Hans Van Vlierberghe, Isabelle Colle, Manuel Morales-Ruiz. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. *Hepatology* Volume 53, Issue 5, pages 1629-1640, May 2011 (impact factor: 10.8).

129. Cheung KJ, Tilleman K, Deforce D, Colle I, Moreno C, Gustot T, Van Vlierberghe H. Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C. *Eur J Gastroenterol Hepatol.* 2011 May 26. [Epub ahead of print] (impact factor: 2.1).

130. S. Jeurissen, H. Van Vlierberghe, H. Denys. Young woman with epithelioid hemangioendothelioma. *Belg J Med Oncol* 2011; 5: 105-7.

131. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, Terg R, Silva MO, Ferenci P, Stauber R, Gschwantler M, Weltman M, McCaughan G, Dore G, Harley H, Sievert W, Sasadeusz J, Roberts S, Cheng W, Horsmans Y, Nevens F, Van Vlierberghe H, Moreno C, Lima MP, Parana R, Lyra LG, Mendes-Correa C, Focaccia R, Goncalves FL Jr, Cooper C, Lalonde R, Yoshida E, Bourliere M, Bronowicki JP, Couzigou P, Grange JD, Marcellin P, Mathurin P, Trepo C, Zarski JP, Benhamou Y, Pol S, Hezode C, Berg T, Lueth S, Goeser T, Wedemeyer H, Mauss S, Rasenack J, Zeuzem S, Weidenbach H, Baruch Y, Lurie Y, Shouval D, Nimer A, Benari Z, Colombo M, Ascione A, Andreone P, Reesink H, van Hoek B, Drenth J, Flisiak R, Horban A, Kryczka W, Jablkowski M, Kazek EJ, Esteban R, Sanchez-Tapias JM, Trapero M, Diago M, Garcia-Samaniego J, Romero M, Muellhaupt B, Gerlach T, Weiland O, Dusheiko G, Mutimer D, Agarwal K, Foster GR, Brown A, Pockros PJ, Godofsky EW, Freilich BL, Galati J, Ryan M, Smith C, Bzowej N, Davis G, Everson G, Gitlin N, Gordon SC, Savides T, Lawitz EJ, Nelson D, Poordad F, Rodriguez-Torres M, Luketic VA, Schiff ER, Szabo G, Younossi Z, Afdhal N, Arora S, Bernstein D, Jacobson IM, Kwo P, Strohecker J, Patel K, Fried MW, Reddy KR, Sulkowski M. Telaprevir for retreatment of HCV infection. *N Engl J Med.* 2011 Jun 23;364(25):2417-28. (impact factor 50).

132. F. Desideri, H. Van Vlierberghe. Necrotizing acute pancreatitis following therapeutic plasmapheresis in HCV-related cryoglobulinemia. *Acta Gastroenterologica Belgica* 2011, Vol74(2): 355-358 (Impact factor: 0.86).

133. Lambert B, Sturm E, Mertens J, Oltenfreiter R, Smeets P, Troisi R, Van Vlierberghe H, Defreyne L. Intra-arterial treatment with (90)Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. *Eur J Nucl Med Mol Imaging.* 2011 Jul 27. [Epub ahead of print] (Impact factor: 5).

134. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F, Adler M, Delwaide J, Horsmans Y, van Vlierberghe H, Reesink HW, Richter C, Afdhal N, Araya V, Arora S, Balart L, Bennett M, Berk B, Bernstein D, Bloomer J, Brown R Jr, Bzowej N, Chasen R, Cochran J, Crippin J, Davis G, Davis M, DeJesus E, Di Bisceglie A, Dieterich D, Esposito S,

Everson G, Flamm SL, Franco J, Freilich B, Fried MW, Ghalib R, Godofsky E, Gordon S, Howell C, Hutson W, Jacobson I, Jonas M, Kaufman B, Kwo P, Lawitz E, Lucey M, Lyons M, Martin P, Muir A, Mullen K, Nelson D, Nguyen T, Pockros P, Poordad FF, Reindollar R, Reinus J, Rodriguez-Torres M, Rossaro L, Rubin R, Satyanarayana R, Scott J, Sepe T, Shah N, Sheikh A, Sheikh M, Sherker A, Sherman KE, Strohecker J, Sulkowski M, Szabo G, Terrault N, Tobias H, Tsai N, Vargas H, Workowski K, Wu G, Yapp R, Younes Z, Younossi Z, Zaman A. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med*. 2011 Sep 15;365(11):1014-24.(Impact factor: 50)

135. Schouten JN, Francque S, Van Vlierberghe H, Colle I, Nevens F, Delwaide J, Adler M, Starkel P, Ysebaert D, Gadisseur A, De Winter B, Smits JM, Rahmel A, Michielsens P. The influence of laboratory-induced MELD score differences on liver allocation: more reality than myth. *Clin Transplant*. 2011 Oct 27. doi: 10.1111/j.1399-0012.2011.01538.x. [Epub ahead of print] (Impact factor: 1.8)

136. Blomme B, Francque S, Trépo E, Libbrecht L, Vanderschaeghe D, Verrijken A, Pattyn P, Van Nieuwenhove Y, Van De Putte D, Geerts A, Colle I, Delanghe J, Moreno C, Van Gaal L, Callewaert N, Van Vlierberghe H. N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. *Dig Liver Dis*. 2011 Nov 24. [Epub ahead of print](Impact factor: 2.8)

137. van Keimpema L, Nevens F, Adam R, Porte RJ, Fikatas P, Becker T, Kirkegaard P, Metselaar HJ, Drenth JP, Alexander G, Ballarin R, Becker H, van der Berg AP, Bernardos A, Bresadola F, Buckels J, Candinas D, Castaing D, Descottes B, Ferrón-Orihuela JA, Friman S, Hauss J, Herrera Norena LA, Hirner A, van Hoek B, Hussein H, Leroy V, Lerut JP, Le Treut YP, Manton GA, Margreiter R, Meurisse M, Mir J, Navarro F, Neau-Cransac M, Neuhaus P, Otto G, Pisarski P, Remiszewski P, Risaliti A, Rolles K, Rossi G, Santoro E, Selles CF, Settmacher U, Soriano A, Van Vlierberghe H, Varo E, Zambelli M. European Liver and Intestine Transplant Association. Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. *Transplant Int* 2011 Dec;24(12):1239-45. (Impact factor: 3.2)

139. Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, Sarrazin C, Hoste E, Van Vlierberghe H, Escorsell A, Hafer C, Schreiner O, Galle PR, Mancini E, Caraceni P, Karvellas CJ, Salmhofer H, Knotek M, Ginès P, Kozik-Jaromin J, Rifai K; HELIOS Study Group. Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients with Acute-On-Chronic Liver Failure. *Gastroenterology*. 2012 Jan 13. [Epub ahead of print] (Impact factor: 12)

140. C.Snauwaert, A.Geerts, I.Colle, H.Van Vlierberghe. Ascites: not always the usual suspects. *Acta Gastroenterologica Belgica* 2012; 75(1): 45-48. (Impact factor: 0.82).

141. Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2 to 6: TMC435-C202, a phase IIa, open-label study. *J Hepatol*. 2012 Feb 9. [Epub ahead of print] (Impact factor: 9.3).

142. Heindryckx F, Kuchnio A, Casteleyn C, Coulon S, Olievier K, Colle I, Geerts A, Libbrecht L, Carmeliet P, Van Vlierberghe H. Effect of prolyl hydroxylase domain-2 haploinsufficiency on the hepatocarcinogenesis in mice. *J Hepatol*. 2012 Mar 12. [Epub ahead of print] (Impact factor: 9.3).

143. Blomme B, Fitzpatrick E, Quaglia A, De Bruyne R, Dhawan A, Van Vlierberghe H. Serum protein N-glycosylation in paediatric non-alcoholic fatty liver disease. *Pediatr Obes*. 2012 Apr;7(2):165-73 (Impact factor: 2.65).

144. Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, Neff GW, Ranjan D, Toselli LT, Gane EJ, Scarola J, Alberts RG, Maller ES, Lo CM; Sirolimus Liver Conversion Trial Study Group; Alsina A, Baliga P, Bárcena R, Barnes DS, Befeler AS, Bilbao I, Boudjema K, Bozorgzadeh A, Brown M, Buckel E, Calmus Y, Campos-de la Borbolla L, Cantisani GP, Clavien PA, D'Amico D, del Rio Martin J, de Miranda MP, Descalzi V, Durand F, Elkhammas E, Fawcett J, Firpi-Morell RJ, Fischer L, Gadano A, Gerbes A, Goss J, Gugenheim J, Herrero JJ, Imventarza O, Jones RM, Kim KH, Kneteman N, Koneru B, Lee SK, Levitsky J, Lilly L, MacGilchrist A, Magee J, Mai ML, McAlister V, McCaughan GW, Miele LA, Millson C, Moerli MC, Neuhaus P, Osorio R, Padbury R, Po-Huang L, Pomfret EA, Prieto M, Ramos E, Reddy K, Reggiani P, Reichen J, Rimola A, Roberts J, Rodriguez Sancho LC, Salamé E, Samuel D, Scudamore C, Shenoy S, Sher L, Silva MO, Silva N, Sudan DL, Teperman LW, Thorburn D, Thuluvath P, van Hoek B, van Vlierberghe H, Varo-Perez E, Voigt M, Wiesner RH, Yoshida A. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. *Am J Transplant*. 2012 Mar;12(3):694-705 (Impact factor: 6.05).

145. Snauwaert C, Geerts A, Colle I, Van Vlierberghe H. Ascites: not always the usual suspects. *Acta Gastroenterol Belg.* 2012 Mar;75(1):45-8. (Impact factor: 0.87)
146. Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, De Munter S, Prawitt J, Caron S, Staels B, Van Vlierberghe H, Van Gaal L, Geerts A. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. *Cytokine.* 2012 May 31. [Epub ahead of print] (Impact factor: 3.5)
147. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J; Collaborators (112) Pallota MG, Zarba JJ, Boyer M, Riordan S, Strickland A, Tebbutt N, Thomson B, Borbath I, De Greve J, Van Laethem J, Van Steenberghe W, Van Vlierberghe H, Barrios C, Cosme de Oliveira A, Kotzev I, Takov D, Tchernev K, Burak K, Ma M, Metrakos P, Olweny C, Sherman M, Gamargo Garate C, Martinez-Castillo J, Beaugrand M, Bennouna J, Blanc J, Bronowicki J, Degos F, Dominguez S, Grange J, Hillon P, Raoul J, Seitz J, Blum H, Buggisch P, Caspary W, Dollinger M, Gerken G, Göke B, Gregor M, Greten T, Häussinger D, Hilgard P, Scherübl J, Scheulen M, Schmid R, Spengler U, Wiest R, Zeuzem S, Arvanitakis C, Germanidis G, Katsos I, Figer A, Stemmer S, Amadori D, Bolondi L, Cognetti F, Craxi A, Farinati F, Gridelli C, Martoni A, Mazzaferro V, Porta C, Ricci S, Sangiovanni A, Santoro A, Trevisani F, Cisnero Garza LE, Gane E, O'Donnell A, Leon J, Lozano A, Jassem J, Rydzewska G, Szawlowski A, Tomczak P, Badulescu F, Miron L, Kubyshev V, Bruix J, Forner A, Bustamante Schneider J, Diago M, Montero Alvarez JL, Pascual S, Ruiz del Arbol L, Sangro B, Solá R, Taberero J, Muellhaupt B, Roth A, Jeffrey Evans TR, Falk S, Meyer T, Reeves H, Ross P, Befeler A, Boyer T, Britten C, Byrne T, Garcia-Tsao G, Gold P, Goldenberg A, Heuman D, Kennedy P, Koch A, Llovet JM, Marrero J, Schilsky M, Schwartz J, Schwartz M. SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. *Clin Cancer Res.* 2012 Apr 15;18(8):2290-300. Epub 2012 Feb 28. (Impact factor: 7.3)
148. Heindryckx F, Bogaerts E, Coulon SH, Devlies H, Geerts AM, Libbrecht L, Stassen JM, Carmeliet P, Colle IO, Van Vlierberghe HR. Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model. *Eur J Gastroenterol Hepatol.* 2012 Jul 5. [Epub ahead of print] (Impact factor: 1.8)
149. Seinstra BA, Defreyne L, Lambert B, Lam MG, Verkooijen HM, van Erpecum KJ, van Hoek B, van Erkel AR, Coenraad MJ, Al Younis I, Van Vlierberghe H, van den Bosch MA. Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. *Trials.* 2012 Aug 23;13(1):144. [Epub ahead of print] (Impact factor: 2.5).
150. Vanderschaeghe D, Debruyne E, Van Vlierberghe H, Callewaert N, Delanghe J. CE Analysis of -Globulin Mobility and Potential Clinical Utility. *Methods Mol Biol.* 2012;919:249-57 (Impact factor: 4.0).
151. Blomme B, Heindryckx F, Stassen JM, Geerts A, Colle I, Van Vlierberghe H. Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor. *Mol Cell Biochem.* 2012 Sep 24. [Epub ahead of print] (Impact factor: 2.1).
152. F. Van Hoecke, T. Van Maerken, M. De Bouille, A. Geerts, H. Van Vlierberghe, I. Colle, E. Padalko. Hepatitis E seroprevalence in East and West Flanders, Belgium. *Acta Gastroenterologica Belgica,* 2012 Sep, vol 75(3): 322-324. (Impact factor: 0.63).
153. Heindryckx F, Coulon S, Terrie E, Casteleyn C, Stassen JM, Geerts A, Libbrecht L, Allemeersch J, Carmeliet P, Colle I, Van Vlierberghe H. The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine induced mouse model. *J Hepatol.* 58 (2013), pp. 319-328 (Impact factor: 9.26)
154. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; Delwaide J, Horsmans Y, Van Vlierberghe H, Anderson F, Feinman SV, Heathcote J, Marotta P, Ramji A, Wong F, Peltakian K, Kaita K, Alric L, Ben Ali S, Bigard MA, Bourliere M, Boyer-Darrigrand N, Bronowicki JP, De Ledinghen V, Hezode C, Lebray P, Marcellin P, Maynard-Muet M, Pol S, Poynard T, Tran A, Trepo C, Truchi R, Vallet-Pichard A, Berg T, Guenther R, Lohse AW, Manns M, Niederau C, Schmidt W, Spengler U, Wedemeyer H, Zeuzem S, Carosi G, Colombo M, Craxi A, Rizzetto M, Zignego A, Zuin M, Reymunde A, Buti Ferret M, Esteban R, Afdhal N, Bacon B, Balart L, Bennett M, Box T, Boyer T, Davis M, Flamm S, Freilich B, Galati J, Galler G, Gibas A, Godofsky E, Gordon S, Herrera J, Herrine S, Jacobson I, King J, Kwo P, Lawitz E, Lee W, Levin J, Luketic V, McCone J, McHutchison J, Mullen K, Morgan T, Muir A, Nunes F, Nyberg A, Nyberg L, Pauly MP, Peine C, Poordad F, Ravendhran N, Reindollar R, Riley T,

Rossaro L, Rubin R, Ryan M, Schiff E, Sherman K, Shiffman M, Strauss R, Vierling J, Yapp R, Goodman Z, Colombato L, Curciarello J, Silva M, Tanno H, Terg R, Adler M, Langlet P, Lasser L, Nevens F, Anderson F, Bailey R, Bilodeau M, Cooper C, Feinman S, Heathcote J, Levstik M, Ramji A, Sherman M, Shafran S, Yoshida E, Achim A, Ben Ali S, Bigard MA, Bonny C, Bourliere M, Boyer-Darrigrand N, Bronowicki JP, Canva V, Couzigou P, De Ledinghen V, Guyader D, Hezode C, Larrey D, Latournerie M, Marcellin P, Mathurin P, Maynard-Muet M, Moussalli J, Poupon R, Poynard T, Serfaty L, Tran A, Trepo C, Truchi R, Zarski JP, Berg T, Dikopoulos N, Eisenbach C, Galle P, Gerken G, Goeser T, Gregor M, Klass D, Kraus M, Niederau C, Schlaak J, Schmid R, Thies P, Schmidt K, Thimme R, Weidenbach H, Zeuzem S, Angelico M, Bruno S, Carosi G, Craxi A, Mangia A, Pirisi M, Rizzetto M, Taliani G, Zignego A, Reesink HW, Serejo F, Reymunde A, Rosado B, Torres E, Barcena Marugan R, De La Mata M, Calleja JL, Castellano G, Diago M, Esteban R, Fernandez C, Sanchez Tapias J, Serra Desfilis M, Afdhal N, Al-Osaimi A, Bacon B, Balart L, Bennett M, Bernstein D, Black M, Bowlus C, Boyer T, Dalke D, Davis C, Davis G, Davis M, Everson G, Felizarta F, Flamm S, Freilich B, Galati J, Galler G, Ghalib R, Gibas A, Godofsky E, Gordon F, Gordon S, Gross J, Harrison S, Herrera J, Herrine S, Hu KQ, Imperial J, Jacobson I, Jones D, Kilby A, King J, Koch A, Kowdley K, Krawitt E, Kwo P, Lambiase L, Lawitz E, Lee W, Levin J, Levine R, Li X, Lok A, Luketic V, Mailliard M, McCone J, McHutchison J, Mikolich D, Morgan T, Muir A, Nelson D, Nunes F, Nyberg A, Nyberg L, Pandya P, Pauly M, Peine C, Poleyarnad G, Poordad F, Pound D, Poulos J, Rabinovitz M, Ravendhran N, Ready J, Reddy K, Reindollar R, Reuben A, Riley T, Rossaro L, Rubin R, Ryan M, Santoro J, Schiff E, Sepe T, Sherman K, Shiffman M, Sjogren M, Sjogren R, Smith C, Stein L, Strauss R, Sulkowski M, Szyjowski R, Vargas H, Vierling J, Witt D, Yapp R, Younes Z. Factors that predict response of patients with hepatitis C virus infection to boceprevir. *Gastroenterology*. 2012 Sep;143(3):608-18. (Impact factor 11.6).

155. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. *Lancet Oncol*. 2012 Nov 19. pii: S1470-2045(12)70490-4. doi: 10.1016/S1470-2045(12)70490-4. [Epub ahead of print] (Impact factor: 22.6).

156. Verhelst XP, Troisi RI, Colle I, Geerts A, van Vlierberghe H. Biomarkers for the diagnosis of acute cellular rejection in liver transplant recipients: A review. *Hepatol Res*. 2012 Oct 29. doi: 10.1111/hepr.12012. [Epub ahead of print] (Impact factor: 2.2)

157. Raevens S, De Pauw M, Reyntjens K, Geerts A, Verhelst X, Berrevoet F, Rogiers X, Troisi RI, Van Vlierberghe H, Colle I. Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation. *Eur J Gastroenterol Hepatol*. 2012 Dec 13. [Epub ahead of print] (Impact factor: 1.7).

158. B.Strubbe, A.Geerts, H.Van Vlierberghe, I.Colle. Progressive familial intrahepatic cholestasis and benign recurrent intrahepatic cholestasis: a review. *Acta Gastroenterologica Belgica*, vol 75, N°4: 405-410; 2012 (Impact factor 0.87).

159. Stephanie Coulon, Vanessa Legry, Femke Heindryckx, Christophe Van Steenkiste, Christophe Casteleyn, Kim Ollivier, Louis Libbrecht, Peter Carmeliet, Bart Jonckx, Jean-Marie Stassen, Hans Van Vlierberghe, Isabelle Leclercq, Isabelle Colle, Anja Geerts. Role of vascular endothelial growth factor in the pathophysiology of non-alcoholic steatohepatitis in two mice models. *Hepatology*. 2013 Jan 8. doi: 10.1002/hep.26219. [Epub ahead of print] (impact factor: 11.6).

160. Degré D, Colle I, Van Vlierberghe H, Moreno C. Boceprevir-based tritherapy of HCV-infected Belgian liver-transplanted patients: Preliminary experience. *Liver Transpl*. 2013 Mar 14. doi: 10.1002/lt.23645. [Epub ahead of print] (Impact factor: 3.4).

161. Raevens S, Colle I, Reyntjens K, Geerts A, Berrevoet F, Rogiers X, Troisi RI, Van Vlierberghe H, De Pauw M. Echocardiography for detection of portopulmonary hypertension in liver transplantation candidates: Analysis of cutoff values. *Liver Transpl*. 2013 Apr 13. doi: 10.1002/lt.23649. [Epub ahead of print] (Impact factor: 3.4)

162. T.Maenhout, A.Poll, B.Wuyts, E.Lecocq, H.Van Vlierberghe, M.De Buyzere, J.Delanghe. Microheterogeneity of serum Beta-Hexosaminidase in chronic alcohol abusers in a drivers license regranting program. *Alcoholism, Clinical And Experimental Research*. 23 APR 2013 | DOI: 10.1111/acer.12112 (Impact factor: 3.3)

163. Colle I, Laureys G, Raevens S, Libbrecht L, Leroy JG, Reyntjens K, Geerts A, Rogiers X, Troisi RI, Hoehn H, Schindler D, Hanenberg H, De Wilde V, Van Vlierberghe H. Living related liver transplantation in an adult patient with hepatocellular adenoma and carcinoma 13 years after bone

- marrow transplantation for Fanconi anemia: A case report. *Hepatol Res.* 2013 May 15. doi: 10.1111/hepr.12043. [Epub ahead of print] (Impact factor: 2.2)
164. I. Colle, X. Verhelst¹, A. Vanlander, A. Geerts, H. Van Vlierberghe, F. Berrevoet, X. Rogiers, R. I. Troisi. Pathophysiology and Management of Post Resection Liver Failure. *Acta Chir Belg*, 2013, 113, 155-161. (Impact factor : 0.4).
165. Donckier V, Craciun L, Miqueu P, Troisi RI, Lucidi V, Rogiers X, Boon N, Degré D, Buggenhout A, Moreno C, Gustot T, Sainz-Barriga M, Bourgeois N, Colle I, Van Vlierberghe H, Amrani M, Remmelink M, Lemmers A, Roelen DL, Claas FH, Reinke P, Sawitzki B, Volk HD, Le Moine A, de Hemptinne B, Goldman M. Expansion of Memory-Type CD8+ T Cells Correlates With the Failure of Early Immunosuppression Withdrawal After Cadaver Liver Transplantation Using High-Dose ATG Induction and Rapamycin. *Transplantation.* 2013 Jun 24. [Epub ahead of print] (Impact factor: 3.7).
166. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; Aguilar Melero P, Albillos A, Alessandria C, Angeli P, Arroyo V, Bañares R, Benten D, Bernardi M, Bocci M, Caraceni P, Catalina MV, Chin JL, Coenraad MJ, Coilly A, Concepción M, Cordoba J, de Gottardi A, de la Mata M, Deulofeu C, Domenicali M, Dorn L, Durand F, Elkrief L, Fernandez J, Garcia E, Gatta A, Gerber L, Gerbes A, Ginès P, Grønbæk H, Guevara M, Gustot T, Hausen A, Hopf C, Jalan R, Karlsen S, Laleman W, Lohse AW, Maggioli C, Markwardt D, Martinez J, Marzano A, McCormick P, Mesonero F, Montero Álvarez JL, Mookerjee RP, Morando F, Moreau R, Moreno C, Morrell B, Mortensen C, Nevens F, Pavesi M, Peck-Radosavljevic M, Pereira G, Rizzo A, Rizzetto M, Rodriguez E, Romano A, Saliba F, Samuel D, Sauerbruch T, Simon-Talero M, Solis-Muñoz P, Soriano G, Sperl J, Spindelboeck W, Stauber R, Steib C, Trebicka J, Valla D, Van Vlierberghe H, Verbeke L, Vogel W, Wege H, Welzel T, Wendon J, Willars C, Yago Baenas M, Zaccherini G, Zeuzem S. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology.* 2013 Jun;144(7):1426-37, 1437.e1-9. doi: 10.1053/j.gastro.2013.02.042. Epub 2013 Mar 6. (Impact factor: 12.7)
167. Van Heghe L, Delanghe J, Van Vlierberghe H, Vanhaecke F. The relationship between the iron isotopic composition of human whole blood and iron status parameters. *Metalomics.* 2013 Aug 1. [Epub ahead of print] (Impact factor: 4.1)
168. Troisi RI, Wojcicki M, Tomassini F, Houtmeyers P, Vanlander A, Berrevoet F, Smeets P, Van Vlierberghe H, Rogiers X. Pure Laparoscopic Full-Left Living Donor Hepatectomy for Calculated Small-for-Size LDLT in Adults: Proof of Concept. *Am J Transplant.* 2013 Aug 5. doi: 10.1111/ajt.12362. [Epub ahead of print] (Impact factor: 6.2).
169. Elise Deruytter, Christophe Van Steenkiste, Eric Trépo, Anja Geerts, Hans Van Vlierberghe, Frederik Berrevoet, Bernard de Hemptinne, Xavier Rogiers, Roberto Troisi, Isabelle Colle. Liver transplantation for alcoholic liver disease : a retrospective analysis of recidivism, survival and risk factors predisposing to alcohol relapse. *Acta Gastroenterologica Belgica.* 2013; 76, 282-290. (Impact factor: 0.82).
170. D.Dooremont, J.Decaestecker, D.De Wulf, G.Ghillebert, H.Van Vlierberghe, J.Van Dorpe, F.Baert. Azathiopurine induced serious portal hypertension: a case series of three IBD patients and review of the literature. *Acta Gastroenterologica Belgica.* 2013; 76: 342-346. (Impact factor: 0.82).
171. Vandewynckel YP, Laukens D, Geerts A, Bogaerts E, Paridaens A, Verhelst X, Janssens S, Heindryckx F, Van Vlierberghe H. The paradox of the unfolded protein response in cancer. *Anticancer Res.* 2013 Nov;33(11):4683-94. (Impact factor: 1.7).
172. Paridaens A, Laukens D, Vandewynckel YP, Coulon S, Van Vlierberghe H, Geerts A, Colle I. Endoplasmic reticulum stress and angiogenesis: is there an interaction between them? *Liver Int.* 2014 Jan 2. doi: 10.1111/liv.12457. [Epub ahead of print] (Impact factor: 3.87)
173. Eliene Bogaerts, Femke Heindryckx, Yves-Paul Vandewynckel, Leo Van Grunsvem, Hans Van Vlierberghe. The roles of transforming growth factor-, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review). *INTERNATIONAL JOURNAL OF ONCOLOGY.* DOI: 10.3892/ijo.2014.2286. (Impact factor: 2.65).
174. Jeurissen S, Vogelaers D, Sermijn E, Van Dycke K, Geerts A, Van Vlierberghe H, Colle I. Invasive aspergillosis in patients with cirrhosis, a case report and review of the last 10 years. *Acta Clin Belg.* 2013 Sep-Oct;68(5):368-75. (Impact factor: 0.59).
175. J.P.Mulkay, S.Bourgeois, L.Lasser, C.De Galocsy, S.Tomasovic, Y.Horsmans, H.Van Vlierberghe. Characteristics, treatment and virological responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in Belgium: a sub-analysis of the PROPHECY

study. *Acta Gastroenterologica Belgica* 2014; 77(1): 30-40; (impact factor: 0.87).

176. H. Razavi, I. Waked, C. Sarrazin, R. P. Myers, R. Idilman, F. Calinas, W. Vogel, M. C. Mendes Correa, C. Hezode, P. Lazaro, U. Akarca, S. Aleman, I. Balk, T. Berg, F. Bihl, M. Bilodeau, A. J. Blasco, C. E. Brandao Mello, P. Bruggmann, M. Buti, J. L. Calleja, H. Cheinquer, P. B. Christensen, M. Clausen, H. S. M. Coelho, M. E. Cramp, G. J. Dore, W. Doss, A. S. Duberg, M. H. El-Sayed, G. Ergor, G. Esmat, K. Falconer, J. Felix, M. L. G. Ferraz, P. R. Ferreira, S. Frankova, J. Garca-Samaniego, J. Gerstoft, J. A. Gira, F. L. Goncalves Jr, E. Gower, M. Gschwantler, M. Guimaraes Pessoa, S. J. Hindman, H. Hofer, P. Husa, M. Kaberg, K. D. E. Kaita, A. Kautz, S. Kaymakoglu, M. Kraiden, H. Krarup, W. Laleman, D. Lavanchy, R. T. Marinho, P. Marotta, S. Mauss, C. Moreno, K. Murphy, F. Negro, V. Nemecek, N. Ormeci, A. L. H. Øvrehus, J. Parkes, K. Pasini, K. M. Peltekian, A. Ramji, N. Reis, S. K. Roberts, W. M. Rosenberg, F. Roudot-Thoraval, S. D. Ryder, R. Sarmento-Castro, D. Semela, M. Sherman, G. E. Shiha, W. Sievert, J. Sperl, P. Starkel, R. E. Stauber, A. J. Thompson, P. Urbanek, P. Van Damme, I. van Thiel, H. Van Vlierberghe, D. Vandijck, H. Wedemeyer, N. Weis, J. Wiegand, A. Yosry, A. Zekry, M. Cornberg, B. Mullhaupt and C. Estes. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. *Journal of Viral Hepatitis*, 2014, 21, (Suppl. 1), 3459. (Impact factor: 3.1).

177. P. Bruggmann, T. Berg, A. L. H. Øvrehus, C. Moreno, C. E. Brandao Mello, F. Roudot-Thoraval, R. T. Marinho, M. Sherman, S. D. Ryder, J. Sperl, U. Akarca, I. Balk, F. Bihl, M. Bilodeau, A. J. Blasco, M. Buti, F. Calinas, J. L. Calleja, H. Cheinquer, P. B. Christensen, M. Clausen, H. S. M. Coelho, M. Cornberg, M. E. Cramp, G. J. Dore, W. Doss, A. S. Duberg, M. H. El-Sayed, G. Ergor, G. Esmat, C. Estes, K. Falconer, J. Felix, M. L. G. Ferraz, P. R. Ferreira, S. Frankova, J. Garca-Samaniego, J. Gerstoft, J. A. Gira, F. L. Goncalves Jr, E. Gower, M. Gschwantler, M. Guimaraes Pessoa, C. Hezode, H. Hofer, P. Husa, R. Idilman, M. Kaberg, K. D. E. Kaita, A. Kautz, S. Kaymakoglu, M. Kraiden, H. Krarup, W. Laleman, D. Lavanchy, P. Lazaro, P. Marotta, S. Mauss, M. C. Mendes Correa, B. Mullhaupt, R. P. Myers, F. Negro, V. Nemecek, N. Ormeci, J. Parkes, K. M. Peltekian, A. Ramji, H. Razavi, N. Reis, S. K. Roberts, W. M. Rosenberg, R. Sarmento-Castro, C. Sarrazin, D. Semela, G. E. Shiha, W. Sievert, P. Starkel, R. E. Stauber, A. J. Thompson, P. Urbanek, I. van Thiel, H. Van Vlierberghe, D. Vandijck, W. Vogel, I. Waked, H. Wedemeyer, N. Weis, J. Wiegand, A. Yosry, A. Zekry, P. Van Damme, S. Aleman and S. J. Hindman. Historical epidemiology of hepatitis C virus (HCV) in selected countries. *Journal of Viral Hepatitis*, 2014, 21, (Suppl. 1), 533. (Impact factor: 3.1).

178. H. Wedemeyer, A. S. Duberg, M. Buti, W. M. Rosenberg, S. Frankova, G. Esmat, N. Ormeci, H. Van Vlierberghe, M. Gschwantler, U. Akarca, S. Aleman, I. Balk, T. Berg, F. Bihl, M. Bilodeau, A. J. Blasco, C. E. Brandao Mello, P. Bruggmann, F. Calinas, J. L. Calleja, H. Cheinquer, P. B. Christensen, M. Clausen, H. S. M. Coelho, M. Cornberg, M. E. Cramp, G. J. Dore, W. Doss, M. H. El-Sayed, G. Ergor, C. Estes, K. Falconer, J. Felix, M. L. G. Ferraz, P. R. Ferreira, J. Garca-Samaniego, J. Gerstoft, J. A. Gira, F. L. Goncalves Jr, M. Guimaraes Pessoa, C. Hezode, S. J. Hindman, H. Hofer, P. Husa, R. Idilman, M. Kaberg, K. D. E. Kaita, A. Kautz, S. Kaymakoglu, M. Kraiden, H. Krarup, W. Laleman, D. Lavanchy, P. Lazaro, R. T. Marinho, P. Marotta, S. Mauss, M. C. Mendes Correa, C. Moreno, B. Mullhaupt, R. P. Myers, V. Nemecek, A. L. H. Øvrehus, J. Parkes, K. M. Peltekian, A. Ramji, H. Razavi, N. Reis, S. K. Roberts, F. Roudot-Thoraval, S. D. Ryder, R. Sarmento-Castro, C. Sarrazin, D. Semela, M. Sherman, G. E. Shiha, J. Sperl, P. Starkel, R. E. Stauber, A. J. Thompson, P. Urbanek, P. Van Damme, I. van Thiel, D. Vandijck, W. Vogel, I. Waked, N. Weis, J. Wiegand, A. Yosry, A. Zekry, F. Negro, W. Sievert and E. Gower. Strategies to manage hepatitis C virus (HCV) disease burden. *Journal of Viral Hepatitis*, 2014, 21, (Suppl. 1), 6089. (Impact factor: 3.1).

179. Raevens S1, Coulon S, Van Steenkiste C, Colman R, Verhelst X, Van Vlierberghe H, Geerts A, Perkmann T, Horvatits T, Fuhrmann V, Colle I. Role of angiogenic factors/cell adhesion markers in serum of cirrhotic patients with hepatopulmonary syndrome. *Liver Int.* 2014 Apr 28. doi: 10.1111/liv.12579. [Epub ahead of print]. (Impact factor: 3.87).

180. Balmer ML, Slack E, de Gottardi A, Lawson MA, Hapfelmeier S, Miele L, Grieco A, Van Vlierberghe H, Fahrner R, Patuto N, Bernsmeier C, Ronchi F, Wyss M, Stroka D, Dickgreber N, Heim MH, McCoy KD, Macpherson AJ. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. *Sci Transl Med.* 2014 May 21;6(237):237ra66. doi: 10.1126/scitranslmed.3008618. (Impact factor 10.7).

181. Vandewynckel YP1, Laukens D, Geerts A, Vanhove C, Descamps B, Colle I, Devisscher L, Bogaerts E, Paridaens A, Verhelst X, Van Steenkiste C, Libbrecht L, Lambrecht BN, Janssens S, Van Vlierberghe H. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent. *Eur J Gastroenterol Hepatol.* 2014 Aug;26(8):861-70. doi: 10.1097 (Impact factor: 1.9)

182. E. Coussens, S. Rogge, M. Haspelslagh, A. Geerts, X. Verhelst, H. Van Vlierberghe, R. I. Troisi,

- I.Colle. Cutaneous infection by *Alternaria infectoria* in a liver transplant patient: a case report. *Acta Gastroenterologica Belgica*, 2014 vol 77(2): 256-258. (Impact factor 0.87).
183. P.Van Damme, W.Laleman, P.Stärkel, H.Van Vlierberghe, D.Vandijck, S.J. Hindman, H.Razavi, C.Moreno. Hepatitis C epidemiology in Belgium. *Acta Gastroenterologica Belgica*, 2014 vol 77(2): 277-279. (Impact factor 0.87).
184. P.Stärkel, D.Vandijck, W.Laleman, P.Van Damme, C.Moreno, S.Hindman, H.Razavi, H.Van Vlierberghe. The disease burden of hepatitis C in Belgium: development of a realistic disease control strategy. *Acta Gastroenterologica Belgica*, 2014 vol 77(2): 280-284. (Impact factor 0.87).
185. D.Vandijck, C.Moreno, P.Stärkel, P.Van Damme, H.Van Vlierberghe, S.J.Hindman, H.Razvi, W.Laleman. Current and future health and economic impact of hepatitis C in Belgium. *Acta Gastroenterologica Belgica*, 2014 vol 77(2): 285-290. (Impact factor 0.87).
186. Raevens S, De Pauw M, Geerts A, Berrevoet F, Rogiers X, Troisi RI, Van Vlierberghe H, Colle I. Prevalence and outcome of diastolic dysfunction in liver transplantation recipients. *Acta Cardiol*. 2014 Jun;69(3):273-80. (Impact factor: 0.6).
187. Vandewynckel YP, De Rycke R, Bogaerts E, Van Vlierberghe H. Intestinal metaplasia in an orthotopic mouse model for hepatocellular carcinoma. *Dig Liver Dis*. 2014 Jul 30. pii: S1590-8658(14)00430-7. doi: 10.1016/j.dld.2014.07.003. [Epub ahead of print]. (Impact factor: 2.9).
188. Yüksel M, Laukens D, Heindryckx F, Van Vlierberghe H, Geerts A, Wong FS, Wen L, Colle I. Hepatitis mouse models: from acute-to-chronic autoimmune hepatitis. *Int J Exp Pathol*. 2014 Aug 12. doi: 10.1111/iep.12090. [Epub ahead of print] (Impact factor: 2.0).
189. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study., Ferenci P, Gschwantler M, Maieron A, Bourgeois S, Mulkay JP, Moreno C, Nevens F, Van Vlierberghe H, Gervain J, Szalay F, Baruch Y, Ben-Ari Z, Lurie Y, Puoti M, Rizzadini G, Villa E, Janczewska E, Mazur W, Olszok I, Calinas FA, Sarmiento e Castro R, Tato Marinho R, Caruntu FA, Curescu M, Rugina S, Chulanov V, Maevskaia M, Yakovlev AA, Calleja Panero JL, Diago Madrid M, Planas Villa R, Romero Gomez M, Balart L, Bernstein D, Box TD, Crespo I, Enayati P, Lidofsky S, Luketic VA, Mantry P, Marbury TC, Nyberg A, Nyberg LM, Patel V, Pearlman BL, Reddy RK, Yangco BG, Younes Z, Bredeek F, Cooper C, Cote P, Elkhashab M, Longpre D, Ramji A, Tam E, Wyles D, Aspinall R, Brown A, Cramp M, Dusheiko J, Foxton D, Foxton M, Priest M, Ryder S, Bennett M, Bernstein D, Bhandari BR, Box TD, Davis M, Eisner M, Fessel J, Freilich B, Gathe J, Geenen D, Green S, Hanje J, Hanson J, Hassanein T, Herring R, Kayli Z, Kemmer N, King W, Lalezari J, Manos P, Nahass R, Oguchi G, Osiyemi O, Overcash S, Ramgopal M, Rausher D, Ravinuthala R, Rhame F, Rodriguez J, Ruane P, Rustgi V, Sepe T, Saag M, Santoro J, Tsai N, Younes Z, Younossi Z, Yozviak J. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. *N Engl J Med*. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4. (Impact factor: 54.4).
190. Vandewynckel YP, Geerts A, Verhelst X, Van Vlierberghe H. Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma. *Clin Case Rep*. 2014 Feb;2(1):4-6.

A3)

1. H. Van Vlierberghe. Tetrahydrofuraanhepatitis. *Belgisch Tijdschrift voor Geneeskunde*, volume 51, nr. 1, 70-72, 1995.
2. H. Van Vlierberghe, D. Voet, F. De Smet, M. De Vos, M. Afschrift, A. Elewaut. Biliare Ascariasis.

- Belgisch Tijdschrift voor Geneeskunde, volume 51, nr. 21, 1501-1503, 1995.
3. H. Van Vlierberghe, M. De Vos. Medicamenteuze behandeling van inflammatoir darmlijden. Belgische Tijdschrift voor Geneeskunde, volume 52, nr. 11, 717-720, 1996.
4. H. Van Vlierberghe. Terugkeer van reis met diarree. Belgisch Tijdschrift voor Geneeskunde, volume 53, nr. 3, 161-164, 1997.
5. H. Van Vlierberghe, L. Messiaen, M. Hautekeete, A. Elewaut, A. De Paepe. Erfelijke hemochromatose : van Kelten en IJzeren Tijdperk tot genetische diagnose. Belgisch Tijdschrift voor Geneeskunde, volume 55, nr. 2, 143-147, 1999.
6. H. Van Vlierberghe. Vragenbus : hemochromatose-hemosiderose. Belgisch Tijdschrift voor Geneeskunde, volume 55 nr. 5, 385,1999.
7. H. Van Vlierberghe. Brieven aan de redactie : Erfelijke hemochromatose : van Kelten en IJzeren Tijdperk tot genetische diagnose. Belgisch Tijdschrift voor Geneeskunde, volume 55, nr. 10, 770-771, 1999.
8. N.M.Keereman, H.Van Vlierberghe. De behandeling van hepatitis C bij intraveneuze druggebruikers: een stand van zaken. Belgisch Tijdschrift voor Geneeskunde, volume 58, nr. 4, 240-244, 2002.
9. N.Stoens, H.Van Vlierberghe. Pyleflebitis: casuïstiek en literatuuroverzicht. Belgisch Tijdschrift voor Geneeskunde, volume 58, nr 10, 700-704, 2002.
10. F.De Winter, B.Brans, B.Lambert, F.Gemmel, K.Van Laere, L.Defreyne, H.Van Vlierberghe, B de Hemptinne, K.Bacher, R.A.Dierckx. Locoregionale 131 I lipiodoltherapie bij de behandeling van het hepatocellulair carcinoom. Belgisch Tijdschrift voor Geneeskunde, volume 59, Nr 8, 532-541, 2003.
11. A.Geerts, I.Colle, H.Van Vlierberghe, M.De Vos. Een enterovaginale fistel secundair aan een geperforeerd ontstoken divertikel van Meckel. Belgisch Tijdschrift voor Geneeskunde, volume 59, Nr 8, 542-548, 2003.
12. H.Van Vlierberghe, M.Bogaert. Vitaminen en Mineralen: wetgeving en toxiciteit. Belgisch Tijdschrift voor Geneeskunde, volume 59, nr 23, 1455-1459, 2003.
13. H.Van Vlierberghe. Boekbespreking: Vitamins and minerals: health benefits and intake recommendations. Belgisch Tijdschrift voor Geneeskunde, volume 60, nr 2, 152, 2004.
14. I.Colle, L.Vandenbussche, H.Van Vlierberghe, R.Troisi, M.De Vos, B.de Hemptinne. Voedingstoestand van levertransplantatiekandidaten. Belgisch Tijdschrift voor Geneeskunde, volume 61, nr 10, 766-773, 2005.
15. C. Van Steenkiste, H. Van Vlierberghe, I. Colle. Een praktisch overzicht van hepatitis C. Tijdschrift voor geneeskunde 2007; 63: 140-151.
16. H.Van Vlierberghe, I.Colle, L.Colenbie, K.Vandewoude, R.Troisi, B.de Hemptinne. De MELD-score: naar een verbetering van de orgaanallocatie bij levertransplantatie.Tijdschrift voor geneeskunde 2007; 63(6): 251-255.
17. B.Van Imschoot, I.Colle, H.Van Vlierberghe. Het klinisch gebruik van niet-invasieve tests voor leverfibrose. Patient care, september-oktober 2007, p.34-39.
18. I.Colle, H.Van Vlierberghe. Portopulmonale hypertensie. Tijdschrift voor Geneeskunde, 2007; 63(22): 1138-1143.
19. K.Gorleer, I.Colle, H.Van Vlierberghe. Alcoholische levercirrose, een indicatie voor levertransplantatie? Tijdschrift voor Geneeskunde, 2008; 64(13), p 691-694.
20. C. Van Steenkiste, I. Colle, M. De Vos, L. Van Wallegghem. A.M. Dhondt, H. Van Vlierberghe. Een patiënt met acute abdominale pijn en krachtsverlies. Tijdschrift voor Geneeskunde 2008;64(19):998-1003.
21. A.Temmerman, B.Poppe, L.Ferdinande, A.Geerts, H.Van Vlierberghe, I.Colle. Acute zwangerschapssteatose: een zeldzame complicatie tijdens de zwangerschap. Tijdschrift voor Geneeskunde, 2009; 65(11): 510-515.
22. M.Dekeyser, D.De Looze, B.Poppe, H.Van Vlierberghe, M.De Vos. Recidiverende acute pancreatitis bij een adolescent. Tijdschrift voor Geneeskunde, 2010; 66(9): 447-452.
23. S.Van Cleven, H.Peeters, D.De Looze, M.De Vos, A.Geerts, X.Rogiers, R.Troisi, B.de Hemptinne, L.Defreyne, P.Vanlangenhove, I.Colle, H. Van Vlierberghe. Aanpak en uitkomst van galwegverwikkelingen na levertransplantatie. Tijdschrift voor Geneeskunde 2011; 67(9): 421-430.
24. B.De Cuyper, K.De Schryver, X.Verhelst, A.Geerts, I.Colle, H.Van Vlierberghe. Levertransplantatie voor alcoholisch leverlijden: gelijke kansen voor de alcoholicus? Tijdschrift voor Geneeskunde 2013; 69(2): 69-75.

Projects Pharmacy sponsored and university driven research around viral hepatitis, liver transplantation and hepatocellular carcinoma.

GOA project (1/1/2007-31/12/2010): Ontwikkeling van methodologie voor de karakterisatie van serum/plasma eiwit glycosylatiepatronen. Toepassingen in de klinische hepatologie, endocrinologie, oncologie en dopingsbestrijding. 1.000.000 .

Foundation Fournier-Majoire for Innovation (Koning Boudewijn stichting) (1/5/2008-30/4/2011) (samen met VIB Gent, UCL, KUL). New blood test for early HCC: glycome marker. 700.000 .

Fundamenteel klinisch mandaat FWO (Maître de Recherches Cliniques du Fonds de la Recherche Scientifique - Flandre (Belgique), Senior Clinical Investigator of the Research Foundation - Flanders (Belgium)) (1 oktober 2010-)

GOA project (1/1/2012-31/12/2016): Transmission of the hepatitis C virus: from understanding the mechanisms to clinical applications. (projectnummer 01G01712) (Promotoren: G.Leroux-Roels, P.Meuleman, H.Van Vlierberghe, X.Rogiers) (bedrag: 1.537.000).

FWO project: (01/01/2012 - 31/12/2015): Rol van ER stress in de angiogenese geassocieerd aan lever cirrose en portale hypertensie (projectnummer: G075112N) (Promotoren: I.Colle, A.Geerts, H.Van Vlierberghe, L.Van Grunsven (VUB)) (bedrag: 279.592 + 80.000).

FWO project: (01/01/2012 - 31/12/2015): Invloed op angiogenese en ER stress en hun effect op chemoresistentie, door de inhibitie van PlGF in een hepatocellulair carcinoom muismodel (projectnummer: G015612N) (Promotoren: H.Van Vlierberghe, I.Colle) (bedrag: 243.274)

Projectoproep Kankerplan actie 29 (projecten voor translationeel onderzoek)(FOD Volksgezondheid) (juli 2012-juni 2015). Project Title: Messenger RNA based immunotherapy for hepatocellular carcinoma. (KPC_29_001) (Promotoren: H.Reynaert (UZ Brussel), H.Van Vlierberghe, I.Colle, A.Geerts (UZ Gent), K.Thielemans (VUB) (jaarlijks bedrag van 252083 wordt voorzien voor de duur van 3 jaar: 756249).

FWO project (01/01/2013-31/12/2016). Het verband tussen hypoxie en progenitor cellen bij carcinogenese in de lever. (Project nummer G033313N). Promotor: H.Van Vlierberghe/Co-promotor. L.Van Grunsven (VUB) (bedrag: 320.000).

Memberships EASL
ESOT
BASL
BLIC

Other Relevant Information